Otenabant (CP-945,598) is a drug which acts as a potent and highly selective CB1antagonist.[1] It was developed by Pfizer for the treatment of obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.[3]
^Kim MA, Yun H, Kwak H, Kim J, Lee J (2008). "Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist". Tetrahedron. 64 (48): 10802–10809. doi:10.1016/j.tet.2008.09.057.
^Woods SC (November 2007). "The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction". Journal of the American Academy of Physician Assistants. Suppl Endocannabinoid (11): 7–10. doi:10.1097/01720610-200711000-00005. PMID 18047036. S2CID 25472128.
^"Pfizer Pharmaceutical News and Media - Pfizer: One of the world's premier biopharmaceutical companies". www.pfizer.com.
This cannabinoid related article is a stub. You can help Wikipedia by expanding it.
otenabant, drug, which, acts, potent, highly, selective, antagonist, developed, pfizer, treatment, obesity, development, this, application, been, discontinued, following, problems, seen, during, clinical, similar, drug, rimonabant, clinical, dataatc, codenonei. Otenabant CP 945 598 is a drug which acts as a potent and highly selective CB1 antagonist 1 It was developed by Pfizer for the treatment of obesity 2 but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant 3 OtenabantClinical dataATC codenoneIdentifiersIUPAC name 1 8 2 chlorophenyl 9 4 chlorophenyl 9H purin 6 yl 4 ethylamino piperidine 4 carboxamideCAS Number686344 29 6 YPubChem CID10052040ChemSpider8227602 NUNIIJ8211Y53EFKEGGD09362 YChEMBLChEMBL562668 NCompTox Dashboard EPA DTXSID20988316Chemical and physical dataFormulaC 25H 25Cl 2N 7OMolar mass510 42 g mol 13D model JSmol Interactive imageSMILES CCNC1 CCN CC1 C2 NC NC3 C2N C N3C4 CC C C C4 Cl C5 CC CC C5Cl C O NInChI InChI 1S C25H25Cl2N7O c1 2 31 25 24 28 35 11 13 33 14 12 25 22 20 23 30 15 29 22 34 17 9 7 16 26 8 10 17 21 32 20 18 5 3 4 6 19 18 27 h3 10 15 31H 2 11 14H2 1H3 H2 28 35 NKey UNAZAADNBYXMIV UHFFFAOYSA N N N Y what is this verify See also editCannabinoid receptor antagonistReferences edit Kim MA Yun H Kwak H Kim J Lee J 2008 Design chemical synthesis and biological evaluation of novel triazolyl analogues of taranabant MK 0364 a cannabinoid 1 receptor inverse agonist Tetrahedron 64 48 10802 10809 doi 10 1016 j tet 2008 09 057 Woods SC November 2007 The endocannabinoid system novel pathway for cardiometabolic Risk factor reduction Journal of the American Academy of Physician Assistants Suppl Endocannabinoid 11 7 10 doi 10 1097 01720610 200711000 00005 PMID 18047036 S2CID 25472128 Pfizer Pharmaceutical News and Media Pfizer One of the world s premier biopharmaceutical companies www pfizer com nbsp This cannabinoid related article is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Otenabant amp oldid 1075453152, wikipedia, wiki, book, books, library,
